<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799121</url>
  </required_header>
  <id_info>
    <org_study_id>CTP005</org_study_id>
    <nct_id>NCT02799121</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers</brief_title>
  <official_title>A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective case series is to gain additional clinical experience in the treatment of&#xD;
      diabetic foot ulcers, by documenting and relating patient history (including baseline wound&#xD;
      characteristics) and clinical outcomes (incidence of healing, rate of healing, and patient&#xD;
      and physician satisfaction) in a group of study participants for whom the ReGenerCell™&#xD;
      Autologous Cell Harvesting Device (ReGenerCell™) is used in combination with conventional&#xD;
      therapy for the closure of diabetic foot ulcers (DFUs). Participants will receive&#xD;
      ReGenerCell™ treatment in addition to standard care (debridement, cleansing, dressings,&#xD;
      offloading).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Wound Closure</measure>
    <time_frame>26 Weeks</time_frame>
    <description>100% Re-epithelialisation of wound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound size</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Objectively measured ulcer area cmxcm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuro-QoL</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Quality of Life short questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ReGenerCell™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReGenerCell™ Autologous Cell Harvesting Device</intervention_name>
    <arm_group_label>ReGenerCell™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has stable diabetes mellitus according to investigators clinical judgement&#xD;
&#xD;
          -  Diabetic foot Ulcer&#xD;
&#xD;
               -  Groups 1 and 2: Ulcer surface area between 3 cm2 and 100 cm2 (inclusive)&#xD;
&#xD;
               -  Group 1: 12-24 weeks in duration, no directly visible tendon or bone (University&#xD;
                  of Texas Ulcer grade 1A)&#xD;
&#xD;
               -  Group 2: &gt;3 weeks in duration, University of Texas Ulcer grade 1B, 2A, 2B, 3A, 3B&#xD;
&#xD;
          -  No superficial skin infection (of the ulcer area) requiring intervention&#xD;
&#xD;
          -  Adequate offloading and compliance must be achievable&#xD;
&#xD;
          -  The patient is 18 years of age or older&#xD;
&#xD;
          -  The patient is willing to complete all follow-up evaluations required by the study&#xD;
             protocol&#xD;
&#xD;
          -  The patient is able to abstain from any other non-standard treatment of the ulcer for&#xD;
             the duration of the study, unless medically necessary&#xD;
&#xD;
          -  The patient agrees to abstain from enrolment in any other interventional clinical&#xD;
             trial for the duration of the study&#xD;
&#xD;
          -  The patient is able to read and understand instructions and give voluntary written&#xD;
             informed consent&#xD;
&#xD;
          -  The patient is able and willing to follow the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring intervention for Peripheral Arterial Disease (PAD) will be excluded&#xD;
             from this study&#xD;
&#xD;
          -  Severe Peripheral Arterial Disease that is not reconstructible&#xD;
&#xD;
          -  Pregnant/lactating females (self-reported or tested, per institutional requirements&#xD;
&#xD;
          -  Use of non-inert dressings (silver, honey etc.) during the past 10 days&#xD;
&#xD;
          -  Subjects who have evidence of connective tissue disorders (e.g. vasculitis or&#xD;
             rheumatoid arthritis) under active treatment&#xD;
&#xD;
          -  The patient is known to have a pre-existing active condition that may interfere with&#xD;
             wound healing, e.g. malignancy, autoimmune disease, immunocompromised blood borne&#xD;
             diseases, the patient has AIDS, is HIV- or Hepatitis-C positive, or currently has a&#xD;
             severe dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma&#xD;
             gangrenosum).&#xD;
&#xD;
          -  The patient is taking, or has taken in the past 60 days, &gt;10mg of corticosteroids per&#xD;
             day.&#xD;
&#xD;
          -  The patient has other concurrent conditions that in the opinion of the investigator&#xD;
             may compromise patient safety or study objectives&#xD;
&#xD;
          -  The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate&#xD;
             solution.&#xD;
&#xD;
          -  The patient is a vulnerable or protected adult&#xD;
&#xD;
          -  The patient is unable to follow the protocol&#xD;
&#xD;
          -  The patient is unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King's College Hospital, London</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

